Lesson plan

Lu AE04621

Lu AE04621 is a dopamine receptor agonist which is or was under development for the treatment of Parkinson's disease but has not been marketed. It is taken orally. The drug is said to be a prodrug of the catecholamine Lu AA40326 and to act as a dual dopamine D 1 and D 2 receptor agonist. Lu AE04621 is or was under development by Lundbeck. As of November 2023, it is in phase 1 clinical trials and has been since at least 2016, but no recent development has been reported since February 2019. The chemical structure of Lu AE04621 has not yet been disclosed. However, it may be a prodrug of 5,6-diOH-DPAT or a related approach.

Back to article

Article summary

Lu AE04621 is a dopamine receptor agonist which is or was under development for the treatment of Parkinson's disease but has not been marketed. It is taken orally. The drug is said to be a prodrug of the catecholamine Lu AA40326 and to act as a dual dopamine D 1 and D 2 receptor agonist. Lu AE04621 is or was under development by Lundbeck. As of November 2023, it is in phase 1 clinical trials and has been since at least 2016, but no recent development has been reported since February 2019. The chemical structure of Lu AE04621 has not yet been disclosed. However, it may be a prodrug of 5,6-diOH-DPAT or a related approach.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.